FdaApplication
NDA 208684
Identifiers
- fda_app_no: NDA208684
Properties
| Property | Value |
|---|---|
| applicant_name | PTC THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2017-02-09 |
Revenue by product
EMFLAZA
| Period | Revenue |
|---|---|
| Q2 2026 | $24.6M |
| Q1 2026 | $21.5M |
| Q3 2025 | $35.2M |
| Q2 2025 | $36.4M |
| Q1 2025 | $47.8M |
| Q3 2024 | $51.9M |
| Q2 2024 | $47.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMFLAZA | DEFLAZACORT | 36MG | TABLET;ORAL |
| EMFLAZA | DEFLAZACORT | 6MG | TABLET;ORAL |
| EMFLAZA | DEFLAZACORT | 30MG | TABLET;ORAL |
| EMFLAZA | DEFLAZACORT | 18MG | TABLET;ORAL |
4 products